Cibc World Markets Corp Acquires 2,660 Shares of Humana Inc. (NYSE:HUM)

Cibc World Markets Corp grew its holdings in shares of Humana Inc. (NYSE:HUM) by 16.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,012 shares of the insurance provider’s stock after purchasing an additional 2,660 shares during the quarter. Cibc World Markets Corp’s holdings in Humana were worth $4,824,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HUM. Pzena Investment Management LLC boosted its position in Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after purchasing an additional 1,103,132 shares during the period. FMR LLC boosted its position in shares of Humana by 23.4% in the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after acquiring an additional 643,291 shares during the period. Retirement Systems of Alabama boosted its position in shares of Humana by 735.9% in the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after acquiring an additional 192,801 shares during the period. Worldquant Millennium Advisors LLC bought a new position in shares of Humana in the third quarter valued at approximately $50,102,000. Finally, Massachusetts Financial Services Co. MA boosted its position in shares of Humana by 42.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 391,657 shares of the insurance provider’s stock valued at $124,053,000 after acquiring an additional 115,820 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Trading Down 1.0 %

HUM stock opened at $267.01 on Thursday. The company has a market capitalization of $32.23 billion, a PE ratio of 26.84, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The company’s 50 day moving average price is $271.43 and its two-hundred day moving average price is $278.21. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.33%. The ex-dividend date is Friday, March 28th. Humana’s payout ratio is 35.58%.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.37% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have recently commented on HUM. Royal Bank of Canada restated an “outperform” rating and issued a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. StockNews.com lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday. Truist Financial raised their price objective on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.